Rezolute (NASDAQ:RZLT) Lowered to “Sell” Rating by Wall Street Zen

Rezolute (NASDAQ:RZLT) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Several other equities analysts have also issued reports on the company. JMP Securities set a $17.00 price objective on Rezolute in a research report on Wednesday, October 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Rezolute in a report on Wednesday, October 8th. Citizens Jmp upped their price target on shares of Rezolute from $9.00 to $17.00 and gave the company a “market outperform” rating in a report on Wednesday, October 29th. Jefferies Financial Group reissued a “buy” rating and set a $20.00 price objective on shares of Rezolute in a research report on Friday, December 5th. Finally, Maxim Group set a $4.00 price objective on shares of Rezolute in a report on Friday. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Rezolute currently has a consensus rating of “Moderate Buy” and an average price target of $9.78.

Rezolute Trading Up 28.6%

Shares of Rezolute stock opened at $1.80 on Friday. The company has a market capitalization of $166.91 million, a PE ratio of -1.94 and a beta of 0.21. Rezolute has a 12 month low of $1.07 and a 12 month high of $11.46. The stock’s fifty day simple moving average is $9.15 and its 200 day simple moving average is $7.15.

Rezolute (NASDAQ:RZLT) last posted its earnings results on Thursday, November 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.09. Analysts predict that Rezolute will post -0.93 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in RZLT. New York State Common Retirement Fund grew its position in Rezolute by 5.6% in the third quarter. New York State Common Retirement Fund now owns 24,600 shares of the company’s stock valued at $231,000 after purchasing an additional 1,300 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Rezolute by 5.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,201 shares of the company’s stock worth $312,000 after buying an additional 1,567 shares in the last quarter. Pale Fire Capital SE lifted its position in Rezolute by 4.2% during the 2nd quarter. Pale Fire Capital SE now owns 49,122 shares of the company’s stock worth $219,000 after buying an additional 2,000 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Rezolute by 5.5% during the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,659 shares of the company’s stock worth $363,000 after buying an additional 2,014 shares during the last quarter. Finally, Huntleigh Advisors Inc. grew its holdings in shares of Rezolute by 16.7% in the 3rd quarter. Huntleigh Advisors Inc. now owns 17,500 shares of the company’s stock valued at $164,000 after acquiring an additional 2,500 shares in the last quarter. Institutional investors and hedge funds own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.